Tharimmune Inc. has applied its Epiclick multispecific antibody engineering platform to expand its pipeline. With Epiclick, the company can combine distinct antibody binding domains, including those derived from previously inaccessible and undruggable epitopes, in either small-format or full-length configurations to target hard-to-reach epitopes.